Skip to content


Volume 10 Supplement 1

de Senectute: Age and Health Forum

  • Lecture presentation
  • Open Access

Antiangiogenic therapy

  • 1
BMC Geriatrics201010 (Suppl 1) :L4

  • Published:


  • Public Health
  • Monoclonal Antibody
  • Tyrosine
  • Tyrosine Kinase
  • Bevacizumab

A brief look at AMD and developments which have completely subverted the therapeutic approach to patients affected by this disease.

New therapies available include: monoclonal antibody inhibitors of VEGF (Peptaganib, Bevacizumab, Ranibizumab) with the protocols currently in use and a brief reference to new anti-angiogenic therapies that include: decoy of VEGF receptor (VEGF Trap, Small Interfering RNA based therapies, Bevasiranib and AGN211745, Sirolimus) and the VEGF cascade of tyrosine kinase inhibitors (Vatalanib, Pazopanib, TG100801, TG101095, AG013958 and AL39324).

Authors’ Affiliations

Director department of Ophthalmology, Santa Marta Hospital, Azienda Policlinico-Vittorio Emanuele, University of Catania, Italy


© Avitabile; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.